
Wikinvest---Alkermes (ALKS)
Alkermes Announces FDA Advisory Committee Recommends Approval Of VIVITROL® For Opioid Dependence
Alkermes, Inc. (NASDAQ: ALKS) today announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee voted 12 to 1 that VIVITROL ® (naltrexone for extended-release injectable suspension) should be approved for the treatment of opioid dependence. Alkermes, Inc. (NASDAQ: ALKS) today announced that the U.S. Food and Drug Administration (FDA) Psychopharmacologic Drugs Advisory Committee voted 12 to 1 that VIVITROL ® (naltrexone for extended-release injectable suspension) should be approved for the treatment of opioid dependence.